| Name | Title | Contact Details |
|---|
Success Healthcare, LLC. is an organization that manages and owns community-based acute care hospitals supported by a management team dedicated to operations and financial excellence. Our goal is to deliver consistent quality cost-efficient patient care, and programs that best serve as well as respect each individual hospital`s distinctive mission and values, its physicians, employees, and community-at-large. To do so, we provide expertise in operations, clinical, and financial resources to each of our hospitals. To deliver quality and compassionate healthcare to our patients through our employees and the physicians who practice in the communities we serve.
Mason Wright Retirement Cmnty is a Springfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Possis Medical, Inc. is a developer, manufacturer and marketer of medical devices, operating in one business segment.
Horizon Services provides a safe and effective place for individuals to receive addiction treatment and begin their journey toward sustainable, fulfilling recovery. Our Mission is to cultivate or restore a sense of hope, self-awareness and community to people impacted by substance use and mental health challenges by providing effective trauma informed prevention, treatment, and recovery services.